|
**Overview**: Scleroderma Panel**Introduction**: The Scleroderma Panel is a diagnostic tool designed to screen for scleroderma using serum samples. In India, systemic sclerosis (scleroderma) affects ~10-20 per 100,000 population (higher in females), with diffuse cutaneous form causing skin tightening, Raynaud's, lung fibrosis, and renal crisis, and limited form associated with anticentromere antibodies. High morbidity from under-testing in rural/low-SES patients with skin thickening or digital ulcers, limited autoantibody labs, delayed immunosuppressive therapy leading to irreversible organ damage or pulmonary hypertension. Per rheumatology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for anti-Scl-70 and anti-centromere antibodies over 1-2 days with high specificity (anti-Scl-70 ~40 percent in diffuse, anti-centromere ~70 percent in limited), valuable for subtype classification and prognosis. This diagnostic falls under autoimmune screening and targets patients with Raynaud's, skin tightening, or interstitial lung disease, addressing accurate detection to guide early immunosuppression and organ monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise scleroderma identification and reducing disability burden. Its serum-based approach ensures reliable autoantibody detection.**Other Names**: Scleroderma Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Anti-Scl-70/centromere standard in scleroderma classification; in India, used in rheumatology clinics.**Purpose**: The test assesses 2 parameters including anti-Scl-70 to guide scleroderma screening, detect autoantibodies, inform subtype/prognosis.**Test Parameters**: 1. Anti-Scl-70, 2. Anti-Centromere.**Pretest Condition**: No fasting required; patients should have Raynaud's or skin changes.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on skin tightening, Raynaud's, dyspnea.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected scleroderma including organ failure, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive anti-Scl-70 indicates diffuse form with high lung risk; anti-centromere indicates limited form with better prognosis, necessitating specialist input.**Specialist Consultation**: Rheumatologists should be consulted for management.**Additional Supporting Tests**: Nailfold capillaroscopy, high-resolution CT chest for confirmation.**Test Limitations**: Autoantibodies not present in all cases; comprehensive approach required.**References**: Indian Journal of Rheumatology 2024, Scleroderma Studies India 2023. |
